The newest Alzheimer’s drugs, Kisunla and Leqembi, are the first to actually slow down Alzheimer’s. How do they compare to each other?
VIDEO + ARTICLE: Kisunla (generic name: Donanemab) slowed cognitive and functional decline 35%. Once-monthly infusions reduced Alzheimer’s plaque 84%.
China is the third country to launch LEQEMBI for sale, to fight Alzheimer’s, following the United States and Japan.
Three FDA-Approved drugs, terazosin, doxazosin, and alfuzosin, have a happy side effect; they boost energy production in brain cells. New studies suggest this slows or prevents Dementia with Lewy Bodies.
The unanimous 11-0 FDA vote clears an exciting path for this new Alzheimer’s drug.
South Korea joined other countries in approving LEQEMBI® (generic lecanemab) for mild cognitive impairment, mild and early Alzheimer’s. Learn how Leqembi is treating Alzheimer’s around the world.
LEQEMBI® is the newest Alzheimer’s drug. It is administered in hospitals via IV. Biogen applied to the FDA for approval of a home version using an “Autoinjector”. See how it works and learn its advantages.
The first doses of the newly approved Alzheimer’s drug “Leqembi” were administered in Louisville. More than 100 people have signed up since then. See why.
MEDICATION: Razadyne (generic galantamine) is an FDA-Approved daffodil extract for Alzheimer’s. Learn how it significantly lowered mortality & eased cognitive decline.
Biogen reprioritize resources allocated to ADUHELM® to advance LEQEMBI®.
This isn’t any ordinary garden! It’s home to a very special group of people living well with Alzheimer’s.
The Housing Learning and Improvement Network looks at the design process and philosophy behind creating a successful Extra Care scheme.
Access to Leqembi, the new Alzheimer’s drug, has been slowed by lengthy diagnoses. The “Fastball” brainwave test could change that — detecting memory decline earlier and speeding access to treatment.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
No spam, only news and updates.
